7/6/2010

The FDA approved a liquid version of Glassia, Kamada's intravenous drug for alpha-1 antitrypsin deficiency, a condition that can lead to lung-tissue damage and emphysema. Kamada said it is looking for a partner to develop the treatment for other indications.

Full Story:
Reuters

Related Summaries